Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, anticipating an update on China's growth prospects and following a string of ...

Merck KGaA’sMRK-1.94%decrease ... sales grow faster than previously expected over the medium term. The life-sciences and chemicals group lifted its mid-term outlook for its electronics business ...

Based outside Boston, MilliporeSigma was formed after Merck KGaA acquired St. Louis-based Sigma-Aldrich Corp. for $17 billion ...

Merck MRK-1.63%decrease; red down pointing triangle KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a significant drop in profits in 2023. At an investment day at its headquarters ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for $600 million, it said ahead of its Capital ...

GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it said ahead of its Capital ...